Rep. Norm Thurston — Voting Record

Bill

Number

H.B. 519 (2025GS)

Sponsor

Rep. Eliason, Steve

Final action

House/ filed 3/7/2025

Outcome

Failed / filed without passage

Summary

What it does

• This bill:
• defines a term;
• prohibits a pharmaceutical manufacturer from restricting, prohibiting, or otherwise interfering with a 340B entity's ability to:
• acquire a 340B drug; or
• participate in the 340B drug discount program; and
• permits the Public Employees' Benefit and Insurance Program to adjust its business practices to mitigate any resulting financial impacts.

Every vote on this bill

Bill text

3
31A-46-311
Health Care Access Amendments
2025 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Steve Eliason
Senate Sponsor: Evan J. Vickers
LONG TITLE
General Description:
This bill addresses the 340B drug discount program.
Highlighted Provisions:
This bill:
defines a term;
prohibits a pharmaceutical manufacturer from restricting, prohibiting, or otherwise 
interfering with a 340B entity's ability to:
acquire a 340B drug; or 
participate in the 340B drug discount program; and
permits the Public Employees' Benefit and Insurance Program to adjust its business 
practices to mitigate any resulting financial impacts.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
ENACTS:
31A-46-311
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1, Section 
31A-46-311
 is enacted to read:
31A-46-311. Prohibited actions with respect to the 340B drug discount program.
(1)
As used in this section,"manufacturer" means a pharmaceutical manufacturer, including 
an agent or affiliate of a pharmaceutical manufacturer.
(2)
A manufacturer may not:
(a)
directly or indirectly restrict or prohibit:
(i)
a pharmacy from contracting with a 340B entity, including by denying the 
pharmacy access to a drug that is manufactured by the manufacturer;
(ii)
a 340B entity from contracting with a pharmacy, including by denying the 340B 
entity access to a drug that is manufactured by the manufacturer;
(iii)
the acquisition, dispensing, or delivery of a 340B drug to any location authorized 
by a 340B entity to receive the drug, unless prohibited by federal law; or
(iv)
a 340B entity from receiving 340B drug discount program pricing for a 340B 
drug, including by imposing a time limitation on a 340B entity to replenish or 
submit a claim for a 340B drug;
(b)
directly or indirectly:
(i)
require a 340B entity to purchase a 340B drug from a supplier if the manufacturer 
would otherwise permit the 340B entity to purchase a drug that is not a 340B drug 
from the supplier; or
(ii)
require a 340B entity to submit any claim data, utilization data, or information 
about a 340B entity's contracts with a third-party as a condition for allowing the 
acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless 
the data or information sharing is required by federal law; or
(c)
interfere with:
(i)
a contract between a pharmacy and a 340B entity; or
(ii)
the ability of a pharmacy and a 340B entity to enter into a contract.
(3)
The Public Employees' Benefit and Insurance Program created in Section 
49-20-103
may adjust the program's business practices to mitigate any financial impacts resulting 
from this section.
(4)
Nothing in this section is to be construed to conflict with federal law.
Section 2. 
Effective Date.
This bill takes effect on 
May 7, 2025
.
2-17-25 5:52 PM